Literature DB >> 27653022

Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine.

Ulrike Gottwald-Hostalek1, Ningling Sun2, Christian Barho3, Steven Hildemann4.   

Abstract

Hypertension is currently one of the greatest global health care challenges. Although many effective drugs are available, combinations of 2 or more medications are often required to meet clinical targets. Combination therapy has several advantages over monotherapy: lower doses of each drug can be used to achieve therapeutic goals; lower doses may lead to fewer adverse events, facilitating patient adherence; and using multiple drugs with different modes of action may be more effective in treating multifactorial diseases, including hypertension. Adherence is an important consideration when requiring patients to self-administer multiple medications; as the number of concurrent medications increases, patient adherence tends to decrease. Recent evidence suggests that fixed-dose combinations (FDCs) may be more effective than free-dose combinations, as they provide all necessary medications in a single convenient tablet/single-pill combination. Among combinations of hypertension medications, a β-blocker such as bisoprolol with a calcium channel blocker such as amlodipine is an effective combination therapy for hypertension, with distinct and complimentary modes of action. With advantages over free-dose combinations, the FDC of bisoprolol/amlodipine is thus an effective and convenient treatment for hypertension, allowing more patients to achieve their therapeutic goals, while potentially reducing the burden of hypertension on health care systems.
© 2016, The American College of Clinical Pharmacology.

Entities:  

Keywords:  amlodipine; bisoprolol; fixed-dose combination therapy; hypertension

Mesh:

Substances:

Year:  2016        PMID: 27653022     DOI: 10.1002/cpdd.309

Source DB:  PubMed          Journal:  Clin Pharmacol Drug Dev        ISSN: 2160-763X


  5 in total

1.  Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.

Authors:  Chana A Sacks; ChangWon C Lee; Aaron S Kesselheim; Jerry Avorn
Journal:  JAMA       Date:  2018-08-21       Impact factor: 56.272

2.  Bioequivalence and Pharmacokinetics of Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablet versus Bisoprolol 5 mg Tablet and Amlodipine 5 mg Tablet: An Open-Label, Randomized, Two-Sequence Crossover Study in Healthy Chinese Subjects.

Authors:  Chaoying Hu; Xiao Hu; Chunhua Wang; Zirun Zhao; Dan Gao; Xiaoping Chen; Dongli Zhou; Yue Huang; Lin Li; Lan Zhang
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859

3.  Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.

Authors:  Ravi Gupta; Christopher J Morten; Angela Y Zhu; Reshma Ramachandran; Nilay D Shah; Joseph S Ross
Journal:  JAMA Health Forum       Date:  2022-05-20

4.  A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.

Authors:  Marcus J Drake; Sally Bowditch; Emilio Arbe; Zalmai Hakimi; Florent Guelfucci; Ikbel Amri; Jameel Nazir
Journal:  BMC Urol       Date:  2017-05-22       Impact factor: 2.264

5.  Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension.

Authors:  Nicola Di Trani; Hsuan-Chen Liu; Ruogu Qi; Dixita I Viswanath; Xuewu Liu; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Nanomedicine       Date:  2021-06-22       Impact factor: 6.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.